Characterization of a Doxorubicin Liposome Formulation by a Novel in Vitro Release Test Methodology Using Column-Switching High-Performance Liquid Chromatography

被引:12
作者
Ohnishi, Naozumi [1 ,2 ]
Tomida, Hiromasa [2 ]
Ito, Yousuke [2 ]
Tahara, Kohei [2 ]
Takeuchi, Hirofumi [2 ]
机构
[1] Eisai & Co Ltd, Pharmaceut Sci & Technol Unit, Kakamigahara, Gifu 5016195, Japan
[2] Gifu Pharmaceut Univ, Lab Pharmaceut Engn, Gifu 5011196, Japan
关键词
doxorubicin; Doxil (R); dialysis; solid-phase extraction; encapsulation; CIRCULATION TIME; POLYETHYLENEGLYCOLS; NANOMEDICINES; ENCAPSULATION; SYSTEM; DRUGS;
D O I
10.1248/cpb.c14-00009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel in vitro release test methodology for a liposome formulation was developed using a column-switching high-performance liquid chromatography (HPLC) system. Doxorubicin (DXR) liposome formulations were used as a model. A DXR liposome formulation was dispersed into a release medium, and the dispersion fluid was directly injected at predetermined time points into the column-switching HPLC system. To evaluate the release profile, this system can be used for determining the released and encapsulated DXR in the liposome formulation separately. Comparison with a conventional in vitro release test methodology by dialysis revealed that the methodology developed by column-switching HPLC had no rate-limiting process of membrane permeation of the drug (which is occasionally observed in the dialysis method). The in vitro release profiles of DXR liposome formulations were well characterized using the method developed by column-switching HPLC, and different in vitro release characteristics were revealed. The developed method did not require a large amount of sample or a complicated pretreatment. In addition, the developed column-switching HPLC system was applicable for characterization of the encapsulation profile of liposome formulations.
引用
收藏
页码:538 / 544
页数:7
相关论文
共 32 条
[1]   Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I [J].
Abdel-Mottaleb, Mona M. A. ;
Lamprecht, Alf .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2011, 37 (02) :178-184
[2]   Inhalable Liposomes of Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism [J].
Bai, Shuhua ;
Ahsan, Fakhrul .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (11) :4554-4564
[3]   A novel USP apparatus 4 based release testing method for dispersed systems [J].
Bhardwaj, Upkar ;
Burgess, Diane J. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 388 (1-2) :287-294
[4]  
Bolotin Elijah M., 1994, Journal of Liposome Research, V4, P455, DOI 10.3109/08982109409037057
[5]   A RIGOROUS THEORY OF REMOTE LOADING OF DRUGS INTO LIPOSOMES [J].
CEH, B ;
LASIC, DD .
LANGMUIR, 1995, 11 (09) :3356-3368
[6]   An overview of liposome lyophilization and its future potential [J].
Chen, Chengjun ;
Han, Dandan ;
Cai, Cuifang ;
Tang, Xing .
JOURNAL OF CONTROLLED RELEASE, 2010, 142 (03) :299-311
[7]   Polymer conjugates as anticancer nanomedicines [J].
Duncan, Ruth .
NATURE REVIEWS CANCER, 2006, 6 (09) :688-701
[8]  
EMA, Reflection Paper on the Data Requirements for Intravenous Iron-Based NanoColloidal Products Developed with Reference to an Innovator Medicinal Product
[9]  
FDA, GUID IND LIP DRUG PR
[10]  
FDA, GUID DOX HY IN PRESS